Skip to main content
main-content

24.07.2018 | Original Article – Clinical Oncology | Ausgabe 11/2018

Journal of Cancer Research and Clinical Oncology 11/2018

The impact of different doses of indocyanine green on the sentinel lymph-node mapping in early stage endometrial cancer

Zeitschrift:
Journal of Cancer Research and Clinical Oncology > Ausgabe 11/2018
Autoren:
Andrea Papadia, Alessandro Buda, Maria Luisa Gasparri, Giampaolo Di Martino, Beatrice Bussi, Debora Verri, Michael D. Mueller
Wichtige Hinweise
Andrea Papadia and Alessandro Buda have equally contributed to the manuscript.
A correction to this article is available online at https://​doi.​org/​10.​1007/​s00432-018-2741-2.

Abstract

Introduction

Aim of the study is to evaluate the impact of different doses of indocyanine green (ICG) on the sentinel lymph-node (SLN) mapping in endometrial cancer (EC).

Materials and methods

A retrospective analysis of EC patients undergoing a laparoscopic SLN mapping at two institutions was performed. Two different injection protocols were used (protocol # 1: 5 mg/ml and a volume of 8 ml; protocol # 2: 1.25 mg/ml and a volume of 4 ml). In every case, the injection was intracervical. The laparoscopic equipment adopted was the same among both institutions. Overall and bilateral detection rates (DR) and median number of retrieved SLNs were calculated. At uni- and multivariate analysis factors (including ICG dose) associated with DR and number of detected SLNs were investigated.

Results

Overall, 168 patients were included. The overall and bilateral DR were 96.3 and 84.5%. Median number of removed SLNs was 3 (0–18). In 56% of the patients, a median number of 6 (1–93) non-SLNs (NSLNs) were removed. Seventeen (10.1%) patients had metastatic SLNs. At multivariate analysis, no factors were associated with bilateral DR. ICG dose was the only factor associated with number of removed SLNs at multivariate analysis.

Conclusion

A larger dose of ICG is associated with a higher number of retrieved SLNs but not with an increased bilateral DR.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt e.Med zum Sonderpreis bestellen!

Sichern Sie sich jetzt Ihr e.Med-Abo und sparen Sie 50 %!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 11/2018

Journal of Cancer Research and Clinical Oncology 11/2018 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.